You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR ALOGLIPTIN BENZOATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ALOGLIPTIN BENZOATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01990300 ↗ Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus Completed Takeda 2011-11-28 The purpose of this survey is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride
NCT02756832 ↗ An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2 Completed Takeda 2016-09-20 The purpose of this study is to evaluate the effect of alogliptin benzoate (VIPIDIA®) on glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2 (T2DM) at Month 6.
NCT02856113 ↗ Phase 3 Alogliptin Pediatric Study Active, not recruiting Takeda Development Center Americas, Inc. Phase 3 2016-11-28 The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg) once daily compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric participants with type 2 diabetes mellitus (T2DM).
NCT02856113 ↗ Phase 3 Alogliptin Pediatric Study Active, not recruiting Takeda Phase 3 2016-11-28 The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg) once daily compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric participants with type 2 diabetes mellitus (T2DM).
NCT03499704 ↗ A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy Recruiting Celltrion Pharm, Inc. Phase 4 2020-02-11 The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 52.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ALOGLIPTIN BENZOATE

Condition Name

Condition Name for ALOGLIPTIN BENZOATE
Intervention Trials
Diabetes Mellitus, Type 2 2
Type 2 Diabetes Mellitus 2
Diabetes Mellitus 1
Non-alcoholic Steatohepatitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ALOGLIPTIN BENZOATE
Intervention Trials
Diabetes Mellitus, Type 2 6
Diabetes Mellitus 5
Non-alcoholic Fatty Liver Disease 1
Fatty Liver 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ALOGLIPTIN BENZOATE

Trials by Country

Trials by Country for ALOGLIPTIN BENZOATE
Location Trials
United States 21
Brazil 4
Mexico 4
Italy 3
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ALOGLIPTIN BENZOATE
Location Trials
California 1
Arkansas 1
Washington 1
Virginia 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ALOGLIPTIN BENZOATE

Clinical Trial Phase

Clinical Trial Phase for ALOGLIPTIN BENZOATE
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ALOGLIPTIN BENZOATE
Clinical Trial Phase Trials
Completed 2
Recruiting 2
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ALOGLIPTIN BENZOATE

Sponsor Name

Sponsor Name for ALOGLIPTIN BENZOATE
Sponsor Trials
Takeda 4
Takeda Development Center Americas, Inc. 1
Celltrion Pharm, Inc. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ALOGLIPTIN BENZOATE
Sponsor Trials
Industry 6
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.